



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
 UNITED STATES PATENT AND TRADEMARK OFFICE  
 WASHINGTON, D.C. 20231  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/017,273	12/12/2001	Alasdair Mark Naylor	PC22013AA00

CONFIRMATION NO. 7030

## FORMALITIES LETTER



\*0C00000007721775\*

Gregg C. Benson  
 Pfizer Inc.  
 Patent Department, MS4159  
 East in Point Road  
 Groton, CT 06340

FAX RECEIVED

SEP 17 2002

PETITIONS OFFICE

Date Mailed: 03/26/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
 CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
 DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

The following item(s) appear to have been omitted from the application:

- Page(s) 123 & 124 of the specification (description and claims).

I. Should applicant contend that the above-noted omitted item(s) was in fact deposited in the U.S. Patent and Trademark Office (USPTO) with the nonprovisional application papers, a copy of this Notice and a petition (and \$130.00 petition fee (37 CFR 1.17(h))) with evidence of such deposit must be filed within **TWO MONTHS** of the date of this Notice. The petition fee will be refunded if it is determined that the item(s) was received by the USPTO.

II. Should applicant desire to supply the omitted item(s) and accept the date that such omitted item(s) was filed in the USPTO as the filing date of the above-identified application, a copy of this Notice, the omitted item(s) (with a supplemental oath or declaration in compliance with 37 CFR 1.63 and 1.64 referring to such items), and a petition under 37 CFR 1.182 (with the \$130.00 petition fee (37 CFR 1.17(h))) requesting the later filing date must be filed

within TWO MONTHS of the date of this Notice.

III. The failure to file a petition (and petition fee) under the above options (I) or (II) within TWO MONTHS of the date of this Notice (37 CFR 1.181(f)) will be treated as a constructive acceptance by the applicant of the application as deposited in the USPTO. **THIS TWO MONTH PERIOD IS NOT EXTENDABLE UNDER 37 CFR 1.136(a) or (b).** In the absence of a timely filed petition in reply to this Notice, the application will maintain a filing date as of the date of deposit of the application papers in the USPTO, and original application papers (i.e., the original disclosure of the invention) will include only those application papers present in the USPTO on the date of deposit.

In the event that applicant elects not to take action pursuant to options (I) or (II) above (thereby constructively electing option (III)), amendment of the specification to renumber the pages consecutively and cancel incomplete sentences caused by any omitted page(s), and/or amendment of the specification to cancel all references to any omitted drawing(s), relabel the drawing figures to be numbered consecutively (if necessary), and correct the references in the specification to the drawing figures to correspond with any relabelled drawing figures, is required. Any drawing changes should be accompanied by a copy of the drawing figures showing the proposed changes in red ink. Such amendment and/or correction to the drawing figures, if necessary, should be by way of preliminary amendment submitted prior to the first Office action to avoid delays in the prosecution of the application.

---

*A copy of this notice MUST be returned with the reply.*

*NY*  
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY

✓ RPO


FAX RECEIVED

SEP 17 2002

PETITIONS OFFICE

Date Mailed: 12/12/2001 Express Mail No: EL710829238USApplication No. filed herewith Docket No. PC22013AADO By sljApplication of Alasdair M. Naylor, et al.Entitled TREATMENT OF MALE SEXUAL DYSFUNCTIONThe following, due        in the U.S. Patent and Trademark Office, has been received there on the date stamped hereon: JC675 U.S. PTO

<input checked="" type="checkbox"/> Specification <u>131</u> pages	<input checked="" type="checkbox"/> Preliminary Amendment (2 copies)
<input checked="" type="checkbox"/> Claims <u>8</u> pages	<input type="checkbox"/> Reply
<input checked="" type="checkbox"/> Abstract <u>1</u> pages	<input type="checkbox"/> Notice of Appeal
<input checked="" type="checkbox"/> Drawing(s) <u>10</u> sheets	<input type="checkbox"/> Brief (3 copies)
<input checked="" type="checkbox"/> Declaration with <input checked="" type="checkbox"/> Power of Attorney	<input type="checkbox"/> Petition for Extension of Time
<input checked="" type="checkbox"/> Assignment & Recordation Cover Sheet (2 copies)	<input type="checkbox"/> Filing of Missing Parts
<input checked="" type="checkbox"/> Letter of Transmittal PTO/SB/05(2/98) 2 copies	<input type="checkbox"/> Express Mail Certificate
<input type="checkbox"/> Disclosure Statement <u>      </u> References	<input type="checkbox"/> Associate Power of Attorney
<input type="checkbox"/> Form PTO-FB-A820	<input type="checkbox"/> Petition for Expedited Issuance for Foreign Filing License
<input checked="" type="checkbox"/> Fee Transmittal PTO/SB/17(2/98) 2 copies	<input type="checkbox"/> Provisional Cover Sheet
<input type="checkbox"/> Fee Address Indication Form	<input checked="" type="checkbox"/> PTO-1390 (DO/EO/US) <u>      </u> pages
<input type="checkbox"/> Priority Document	<input checked="" type="checkbox"/> Computer readable copy of sequence listing
<input checked="" type="checkbox"/> Certified copies of UK 0030647.2; UK 0108730.3; UK 0109910.0; UK 0111037.8; UK 0120679.6; US 09/895,387; and US 09/905,846	<input type="checkbox"/> Paper copy of sequence listing
<input checked="" type="checkbox"/> Consent and Recordation Cover Sheet (2 copies)	<input type="checkbox"/>
<input checked="" type="checkbox"/> Statement verifying identity of sequence submissions	<input type="checkbox"/>

ENTERED BY Cm